A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of Intravenous PCN-101 in Treatment Resistant Depression
Latest Information Update: 10 Jun 2024
At a glance
- Drugs Arketamine (Primary)
- Indications Depression
- Focus Proof of concept; Therapeutic Use
- Sponsors Perception Neuroscience
- 06 Jan 2023 According to an ATAI Life Sciences media release, Primary endpoint (Montgomery Asberg Depression Rating Scale (MADRS) 24 Hours) has not been met.
- 06 Jan 2023 Results presented in an ATAI Life Sciences Media Release.
- 19 Dec 2022 Status changed from active, no longer recruiting to completed.